Document:

Exhibit 10.4

 

RESEARCH AGREEMENT

 

Made in Jerusalem this 15 day of January 2008, by and between:

 

YISSUM RESEARCH DEVELOPMENT COMPANY
OF THE HEBREW UNIVERSITY OF JERUSALEM, of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel (“Yissum”)
of the one part; and

 

INTEC PHARMA LTD, of 12 Hartom St.
Jerusalem 45219; (the “Company”), of the second part;

 

		WHEREAS	the Parties entered into the joint venture for R&D
agreement dated June 1st, 2000 (the JV Agreement 2000) which was extended and amended on October 5th,
2004 (the Extension) and amended again on July 13th, 2005 (the Second Amendment) (the JV Agreement and
the Extension and the Second Amendment shall collectively be referred to as the “JV Agreement”);

 

		WHEREAS	the Parties wish to further continue their joint venture
for R&D under the terms of this Agreement and correspondingly with the JV Agreement, as stipulated and amended hereunder;

 

NOW, THEREFORE, the Parties agree as follows:

 

		1.	Interpretation and Definitions

 

		1.1.	The preamble and appendices annexed to this Agreement constitute
an integral part hereof and shall be read jointly with its terms and conditions.

 

		1.2.	In this Agreement, unless otherwise required or indicated
by the context, the singular shall include the plural and vice-versa, the masculine gender shall include the female gender.

 

		1.3.	The headings of the sections in this Agreement are
for the sake of convenience only and shall not serve in the interpretation of the Agreement.

 

		1.4.	The terms in this Agreement shall have the meaning
as detailed hereunder in section 1.5, and if a meaning has not been attached alongside it hereunder, shall have the meaning as
agreed by the Parties in the JV Agreement.

 

		1.5.	The Parties agree that the terms of the JV Agreement,
inasmuch as they conform with the provisions of this Agreement, shall be valid, stay in full force and bind the parties under
this Agreement, mutatis mutandis. In case of contradiction between terms and/or provisions of this Agreement and the JV Agreement,
the provisions of this Agreement shall prevail.

 

		1.6.	In this Agreement, the following capitalized terms
shall have the meanings appearing alongside them, unless provided otherwise:

 

    	 

    	 

    

 

 

		1.6.1.	“Intec Pharma Development Results”
shall mean all and any inventions, discoveries, know-how, improvements, new uses, methods, processes, compounds, information,
material, products, devices, information and other results of whatsoever nature, whether patentable or not, that are created,
generated, developed or discovered during the course of and/or arising from the performance of any research and development activities
undertaken by the Company (or on its behalf), which (i) are not a part of the Research (as defined in the JV Agreement 2000),
the Additional Research (as defined in the Extension), the Further Research, the Further Research Program and/or the Further Research
Results; and (ii) do not involve any contribution by the University, Prof. Friedman or any other employee or student of the University
(excluding, for the removal of doubt, Mr. David Kirmayer or any other employee of the Company) (hereinafter “Employee
or Student of the University”).

 

		1.6.2.	“Further Research” shall mean the
research, which shall be carried out and conducted, by Researchers pursuant to the Further Research Program hereunder.

 

		1.6.3.	“Further Research Program” shall
mean the program under which the Further Research shall be carried out and conducted by the Researchers, as per Appendix B.

 

		1.6.4.	“Researchers” shall mean Prof.
Micha Friedman (hereinafter: “Prof. Friedman”), on Yissum’s part, or such other person appointed by Yissum
to supervise and to perform the Further Research, if applicable and Mr. David Kirmayer, on Company’s part (hereinafter:
“Mr. Kirmayer”).

 

		1.6.5.	“Further Research Results” shall
mean all and any inventions, discoveries, know-how, improvements, new uses, methods, processes, compounds, information, material,
products, devices, information and other results of whatsoever nature (collectively “Results”), whether patentable
or not, that are created, generated, developed or discovered during the course of the performance of the Further Research and
all patent applications and patents (which shall be added to the list of Registered Patents set forth on Appendix A), covering
any of the Results or any portion thereof

 

		1.6.6.	“University” shall mean the Hebrew
University of Jerusalem and/or each of its branches.

 

		2.	Further Research

 

		2.1.	The Company hereby undertakes to finance performance of
the Further Research in accordance with the Further Research Program or any amendment thereof, and subject to the terms of section
2.4 hereunder.

 

    	2

    	 

    

 

		2.2.	The Further Research shall be conducted by and under
the supervision of Prof. Friedman and the Company. Should Prof. Friedman be unable to complete the Further Research or any of
its stages, for any reason, Yissum shall notify the Company of the identity of a suitable replacement researcher of the same position
and requisite skills as those of Prof Friedman. If the Company does not object to the replacement researcher on reasonable grounds
within twenty (20) days of this notification, the substitute researcher shall be deemed acceptable to the Company. If the Company
objects to the replacement researcher, the Parties shall amicably and in good faith negotiate a suitable replacement researcher
acceptable by the Company. Alternatively, the Company shall have the right to terminate the Further Research, according to section
11 hereunder.

 

		2.3.	The parties undertake to perform all of their duties
under this Agreement diligently and promptly, and, where applicable, according to the Further Research Program.

 

		2.4.	As compensation to Yissum for the performance of the
part of the Further Research to be performed by Prof Friedman or any other scientist or Employee or Student of the University,
subject to section 2.6 hereunder and/or any earlier termination of the Further Research pursuant to the termination section hereunder,
and the compensation due thereupon, if applicable, the Company shall pay Yissum the total sum of sixty four thousand eight hundred
US Dollars ($64,800) (of which $48,000 are to Prof. Friedman’s lab and the rest are Yissum’s overhead) payable as
follows:

 

		1.	Upon execution of this Agreement: $ 16,200.

		2.	$ 16,200 upon the completion of stage I of the attached Further Research Program:
                                                             “Optimization of the lead”.

		3.	$ 16,200: upon the completion of stage II of the attached Further Research Program:
                                                             “A feasibility of API Incorporation”.

		4.	$ 16,200 upon the completion of stage III of the attached Further Research Program: “Mechanism
elucidation of the hardening”.

 

		2.5.	Yissum and/or the University and/or the Researcher
shall be allowed to obtain further finance or grants from other entities for research regarding the Further Research Program provided
that Yissum shall provide Company with all necessary information concerning the finance terms and that such entities providing
the further finance shall not be granted rights in the Further Research and/or Further Research Results prejudicial to the rights
granted to the Company in this Agreement and subject to Company’s prior written approval, that shall not be unreasonably
withheld and if withheld, shall include a reason based written notice to Yissum.

 

		2.6.	Within 30 days of the completion of each of the three
stages described in the attached Further Research Program (i.e. Optimization of the Lead, A feasibility of API Incorporation and
Mechanism Elucidation of the Hardening), and as a condition for the payment of the compensation detailed in section 2.4 hereunder,
Yissum shall present the Company with a written report (the “Further Research Report”) summarizing the Results
of the Further Research accomplished with respect to that stage. Furthermore, Yissum shall use its best efforts to further provide
the Company with any other additional reports and/or details as the Company may reasonably require.

 

    	3

    	 

    

 

		2.7.	Nothing contained in this Agreement shall be construed
as a warranty on the part of Yissum that any Results or inventions will be achieved by the Further Research, or that the Further
Research Results, if any, are or will be commercially exploitable. Yissum makes no warranties whatsoever as to the commercial
or scientific value of the Further Research Results. Notwithstanding the aforementioned in this section, Yissum undertakes and
commits to do everything in its capacity and use its best efforts to achieve results or inventions that shall be of commercial
or scientific value, under the terms of this Agreement.

 

		2.8.	Should the Company choose to, in addition to the terms
agreed between the parties under this Agreement (i) retain the services of Prof Friedman and/or any other Employee or Student
of the University as a consultant in connection with the Further Research and/or the License and/or the Further License (as defined
below); and/or (b) grant any benefit, including but not limited to, cash payments or securities of any kind, to Prof Friedman
and/or any other Employee or Student of the University, it shall do so only through a written agreement executed between the Company
and Yissum.

 

		3.	Ownership

 

		3.1.	All rights and title in all Further Research Results shall be jointly owned by the Parties in equal
parts (and not wholly by Yissum as per the JV Agreement 2000) and will be registered in both their names. All rights and title
in the Intec Pharma Development Results and all patent applications and patents covering any Intec Pharma Development Results or
any portion thereof shall be solely owned by the Company.

 

		3.2.	Yissum shall grant the Company an exclusive and worldwide
license to its rights in and to the Further Research Results under this Agreement (50%), on the same terms and conditions of the
License (as defined in the JV Agreement) granted to the Company under the JV Agreement which shall apply to Yissum’s rights
in and to the Further Research Results, mutatis mutandis (the “Further License”).

 

		3.3.	The Company shall pay Yissum Royalties with respect
to the use of the Further Research Results and the Further License granted by Yissum to the Company hereunder as follows:

 

		3.3.1.	3% royalties from the Net Sales of the Products from the
first date of commercial sale in each country.

 

		3.3.2.	15% of any payment or benefit of any sort or nature the
company may receive from Sub-Licenses.

 

    	4

    	 

    

 

It is hereby clarified for the
avoidance of doubt that the said Royalties shall be paid with the respect to “Products” as defined below. For the purposes
hereof, “Product(s)” means any product and/or product component and/or production supplement and/or process directly
and/or indirectly based on and/or related to the Know-how and/or the Research Results (as defined in the JV Agreement), and/or
the Further Research Results and/or the Intec Pharma Development Results and/or any part thereof.

 

		3.4.	Royalties under this Agreement shall not derogate
from Yissum’s right to Royalties under JV Agreement for other Products, if applicable, provided, that, for the avoidance
of doubt, at any time, Yissum shall not be entitled to receive Royalties or other payments both under this Agreement and the JV
Agreement, for the same Product and/or in respect of the same payments or benefits received by the Company.

 

		3.5.	For the avoidance of doubt, the terms and definitions:
Royalty, Net Sales, Product and Sub-License, shall have the meaning as agreed by the parties in the JV Agreement and shall apply
hereto mutatis mutandis.

 

		3.6.	Company shall be required to pay for Development and
Commercialization per section 8 of the JV Agreement and reimburse Yissum for patent application expenses, if incurred, per section
10 of the JV Agreement in respect of the Further Research Results hereunder.

 

		3.7.	For the avoidance of doubt, the Compensation, Royalties
and expenses detailed in sections 2-3 hereunder, shall constitute the full and only consideration to Yissum under this Agreement,
for whatever reason.

 

		4.	No Financial Report: Yissum is not expected to present any financial report and the expenses
incurred in rendering the Further Research shall be Yissum’s responsibility alone.

 

		5.	Use of Names: The Company shall not make any use of any kind of the name of Prof. Friedman
or Yissum or the Hebrew University without the prior written consent of Yissum, which shall not be unreasonably withheld and provided
not later than 7 days of Company’s request. Notwithstanding the aforegoing, the Company shall not require Yissum’s
consent for any mention of the name of Prof. Friedman or Yissum or the Hebrew University in any applications to official authorities
for regulatory approval, or in the fulfillment of any duty owed to any competent authority (including a duty to make regulatory
filings and/or reports) or in the presentation of activities to potential investors in the Company, potential business partners
and/or collaborators, subject to the aforegoing being bound by customary confidentiality undertakings. Yissum shall not make any
use of any kind of the name of the Company without the prior written consent of the Company, which shall not be unreasonably withheld.

 

    	5

    	 

    

 

		6.	Relationship of the Parties: Neither the Company nor Yissum stand in a relationship of employer
employee with Prof. Friedman. The relationship of the Company and Yissum shall be that of requester – independent contractor.

 

		7.	Dispute Resolution: In all cases in which a dispute shall arise between the Company and
Yissum regarding the Services or any other matter arising under this Agreement, the dispute shall be resolved exclusively and only
in the competent courts of Tel Aviv and both parties hereby irrevocably consents to said jurisdiction.

 

		8.	Authorized Signatories: Signature by an authorized representative of Yissum on this copy
of the document shall constitute Yissum’s approval and agreement to all that is written herein. The Company warrants that
the person signing this agreement is authorized to bind the Company.

 

		9.	Value Added Tax: Amounts mentioned in this Agreement do not include Value Added Tax (VAT),
which shall be added to such amounts as prescribed by law.

 

		10.	No Liability: Yissum, its ultimate parents, affiliates, officers, directors, employees,
agents and contractors, shall not be liable for any and all claims, actions, demands, losses, damages, costs and expenses made
or brought by third parties arising from or in connection with this Agreement or the use of the Further Research Results, except
for loss, damage, liability and expenses resulting from negligence or willful misconduct on the part of Yissum.

 

		11.	Termination:

 

		(a)	Unless terminated in accordance with the provisions of this Agreement, this Agreement shall end
upon the end of the term of the License, as defined under section 5 of the JV Agreement, for the Further Research Results under
this Agreement.

 

		(b)	Each party shall be entitled to terminate this Agreement in the event of a breach by the other
party of its obligations under this Agreement, which is not remedied by the breaching party within 30 days of receipt of written
notice from the non-breaching party.

 

		(c)	Company shall be entitled to terminate this Agreement, upon the occurrence of any of the following
and under the terms hereof:

 

		(i)	by prior 7 days written notice, during the term of 21 days after receipt of the Further Research
Report for stages I or II, if, in its sole discretion, the completion of said stages was not successful.

 

If Agreement was not terminated
by Company during the 21 day term following the receipt of the Further Research Report, it will constitute Company’s approval
to Yissum to continue Further Research of the next stage of the Further Research Program.

 

    	6

    	 

    

 

		(ii)	By prior 14 days written notice, should Prof. Friedman be
unable to complete the Further Research or any of its stages, for any reason, per section 2.2 hereunder.

 

		(d)	Upon termination or expiration of this Agreement, the Further License and
other rights granted to the Company by Yissum under this Agreement shall terminate and shall revert to Yissum.

 

		(e)	Notwithstanding anything in this Agreement stating the contrary (1) no monies
paid to Yissum for the Further Research pursuant to the schedule set forth in section 2.4, hereunder, will be refundable; and (2)
except in the event of termination by the Company for breach by Yissum, the Company shall be liable to pay accrued fees and/or
expenses that are: (i) based on work performed up to the date of termination; and (ii) constitute irrevocable commitments entered
into by Yissum or the Researcher prior to termination and (iii) bind Yissum for the term of not longer than two months following
termination and (iv) that Yissum did not succeed, after using its best efforts, to cancel.

 

		(f)	Sections 1, 3.1, 7, 10 and 11(d) and (e) shall survive the termination or
expiration of this Agreement for any reason. In addition, any termination or expiration of this Agreement shall not release the
Company or Yissum from the performance of any obligation which it was liable to perform prior to such termination or expiration.

 

		12.	Entire Agreement: This Agreement together with the JV Agreement (as amended hereby) constitutes the entire agreement
between the Parties hereto in respect of the subject-matter hereof, and supersedes all prior agreements or understandings between
the Parties relating to the subject-matter hereof. This Agreement may only be amended by a written document signed by the Parties.

 

	Intec Pharma	 	 
	12 Hartom Street P.O. Box 45219	 	 
	Jerusalem 91450	 	 
	Company Name and Address	 	 
	 	 	 
	/s/ Giora Carni	 	15/1/08
	Signature of Authorized Co. Representative	 	Date Signed
	 	 	 
	Yissum hereby agrees and approves:	 	 
	 	 	 
	/s/ Nava Swersky Sofer and Elana Canetti	 	15/1/08
	Yissum Research Development Company of the Hebrew University of Jerusalem	 	Date Signed

 

    	7

    	 

    

 

Prof. Friedman's Agreement:

 

I the undersigned, Prof. Michael
Friedman of the Hebrew University, have reviewed, am familiar with and agree to all of the above terms and conditions. I hereby
undertake to fully cooperate with Yissum in order to ensure its ability to fulfill its obligations hereunder, as set forth herein.

 

	/s/ Michael Friedman	 
	Date signed	 

 

    	8

    	 

    

 

Appendix B

 

Further Research Program

 

Exhibit I – the Research Specification.

 

Submitted to Intecpharm

by Michael Friedman

School of Pharmacy

The Hebrew University of Jerusalem

 

Brief work plan for period 1-Jan-24-2008 to 31-Dec 20 2008

Submitted to Intec Pharma by Professor Michael Friedman’s group

 

Background

A novel buoyant hardening swelling-tablet
platform was offered (see research offer from January 2006). A detailed research plan for the topic was submitted in January 2007.
The basic points are outlined in the document below.

 

		1.	Optimisation of the lead

 

The key parameters that are responsible
for the swelling of the current lead formulation have been spotted. More data will be amassed to verify the assumptions. Thereupon,
a parametric experiment will be performed to optimise the formulation. Preliminary work will be required to define unequivocally
the working windows for each of the formulatory and process parameters. The results will be processed with JMP software, and the
lead formulation will be compounded for full characterisation.

 

The swelling properties of a tablet can
be anisotropic, as reported in various sources in literature. Therefore, the optimal shape should be sought. There are several
large-size tablets approved on the market, i.e. Augmentin 875, which exploit a singular form of a tablet to maximize capacity and
facilitate swallowing. There is also a patent from Depomed on the subject. Similar forms should be considered theoretically, with
calculations of the relative volume of the tablet, and the advantageous ones should be tested with the successful formulation.

 

The lead formulations will be produced
in sufficient a quantity for full characterisation and for a short-term stability as placebo, according to the plan that remains
to be determined.

 

    	9

    	 

    

 

Inputs:

 

·      Materials
and facilities for production and facility time for analyses (available by then both at Intec and at Professor Friedman’s
laboratory);

 

·      Novel
dies and punches for an IR press;

 

·      Engineering
council (possible to obtain from Avner Balshai);

 

·      Time
on JMP software;

 

·      Laboratory
aids (at Professor Friedman’s laboratory).

 

Performance: David Kirmayer.

 

Estimated time needed: six months

 

Output: interim report on the platform development and
characterisation.

 

Milestone: to reach the output by 1 May 2008

 

2.      A feasibility of API incorporation

 

An API, tentatively gabapentin, will be
incorporated and the possible weak points of the design will be discovered. Inherent controlled-release potential of the formulation
will be evaluated. Mechanical consequences of drug release will be evaluated. Mechanical stability-preserving mechanisms (suggested
in the original plan) will be tested in vitro, if needed. The ways to alter the controlled release will be investigated as well.
The loading capacity will be determined per standard humane dose units.

 

Inputs.

 

·      Materials,
including API, and facilities for production and facility time for analyses;

 

·      Laboratory
aids (at Professor Friedman’s laboratory);

 

·      Analytical
support or additional time for performing the analyses.

 

Performance: David Kirmayer

 

Estimated time needed: four months

 

Output: interim report on the product and characterisation.

 

Milestone: to reach the output by 1 October 2008

 

    	10

    	 

    

 

3.      stage 3: Mechanism elucidation of the hardening

 

The dependence of the system’s performance upon the mechanical
properties is a by-design quality. Thus knowing the underlying mechanism of building up the mechanical strength is a key in understanding
the mechanism of gastric retention of the system. The mechanism will be investigated using thermal analysis methods (DSC), chromatography
(HPLC, GPC) and spectral methodology, known in polymer science. This research will be performed in parallel and in accordance with
other branches of development, and may not be finished by the end of calendar 2007th year.

 

Inputs:

 

·      Materials
and facility time for analyses;

 

·      Funding
for the analyses that can not be performed in-house;

 

·      Possibly
external advisor.

 

Performance: David Kirmayer.

 

Estimated time needed: six months

 

Output: interim report on the hardening mechanism of
the platform.

 

Milestone: none

 

    	11Exhibit 10.8

 

ADDENDUM & AMENDMENT

 

To
that certain subscription agreement
of august 6,
2013

By
and between

Intec
pharma
ltd.,
Gabriel capital
management (gp)
ltd.,
Et al

 

THIS ADDENDUM
& AMENDMENT (this “Addendum”) is made and entered into as of
this 20th day of October, 2014 (the “Effective Date”) by and between Intec
pharma ltd.
(the “Company”) and Gabriel Capital
Management (GP) Ltd. (“Gabriel Capital”), and
supplements and amends that certain Subscription Agreement of August 6, 2013 (the “Agreement”) between the
Company, Gabriel Capital, and each of the parties set out in Schedule
A and Schedule
C to the Agreement (each, a “Subscriber,” and collectively, the “Subscribers”).

 

The Company and the Subscribers are also referred to herein
collectively as the “Parties”, and each as a “Party”.

 

	Whereas,	 	the
    Company effected in September 2014 a rights offering for shareholders of the Company, pursuant to which shareholders were
    offered the opportunity to acquire additional shares of the Company at a price per share of NIS 0.60 (the “Rights
    Offering”), and whereas in October 2014 the Company issued shares at such price per share as a result of exercise
    of such rights (the “Exercise of Rights”); and
	 	 	 
	Whereas,	 	there arose between the Parties certain differences of opinion with respect to the correct interpretation of certain provisions of the Agreement, and the correct manner of their application in connection with the Rights Offering and the Exercise of Rights; and
	 	 	 
	Whereas,	 	pursuant to Section 13.5 to the Agreement, the authority to amend the Agreement is given to the Company and Gabriel Capital;

 

Now,
Therefore, in order to reconcile such differences and intending to finally settle and agree upon the correct application
of the Agreement in connection with the Rights Offering and the Exercise of Rights, through a legally binding document, the Company
and Gabriel Capital do hereby agree as follows:

 

		1.	INTERPRETATION 

 

Capitalized terms used in this Addendum and not expressly
defined herein shall have the respective meanings ascribed to them in the Agreement.

 

		2.	APPLICATION OF SECTIONS 3.2, 4 AND 8 TO THE AGREEMENT 

 

		2.1	Notwithstanding the Protection Formula
                                         set forth in Section 8.1 to the Agreement, the number of additional shares to which each
                                         Subscriber shall be entitled as downside protection in connection with the Rights Offering
                                         and the Exercise of Rights, in full satisfaction of its rights under said Section 8.1,
                                         shall be 105 (one hundred five) shares for each 100 (one hundred) Subscription Shares
                                         initially issued to and still held by such Subscriber as of October 1, 2014 (the “Determining
                                         Date”), and subject to the Subscriber’s proof of issuance and holdings
                                         as reasonably required by the Company. For example, in the event a Subscriber was initially
                                         issued 150 Subscription Shares, such Subscriber shall be entitled to receive additional
                                         158 shares.

 

    	Intec
                                         Pharma » Addendum To Subscription Agmt v-7	Page
                                         1 of 3

    	 

    

  

		2.2	Notwithstanding the provisions of
                                         Sections 3.2(iv), 4.2 and 8.2 to the Agreement, the only adjustment to be made to the
                                         Warrants and the Additional Warrants in connection with the Rights Offering and the Exercise
                                         of Rights, other than the technical adjustment published by the Company on September
                                         15, 2014, shall be the reduction of the Exercise Price and the Second Exercise Price
                                         for the Warrants and the Additional Warrants, respectively, to NIS 0.70 (seventy agorot)
                                         per share, as may be further reduced pursuant to Section 8. In the event of the application
                                         of Section 8.1 in a further or subsequent occurrence, then, solely for the purposes
                                         of Section 8.2, the “Investment/Exit Price” (i.e., the updated “Protection
                                         Threshold Price”) shall mean NIS 0.73 (seventy-three agorot) in respect of such
                                         further occurrence. For the avoidance of any doubt, the provisions of this Section 2.2
                                         shall apply to all Warrants and Additional Warrants issued by the Company in connection
                                         with the Agreement (i.e. both to Subscribers and
                                         other recipients of Warrants and Additional Warrants who did not purchase Subscription
                                         Shares but are deemed to be Subscribers for the purposes of the Agreement and to any
                                         other persons who may have received warrants similar to the Warrants granted to the Subscribers
                                         at or about the Closings under the Agreement).  

 

		2.3	The number of Additional Warrants to be granted pursuant to Section 4.1(A) to the Agreement shall
be calculated on the basis of Subscription Shares actually issued to the Subscribers under the Agreement up to and including
the final of the Closing Dates thereunder; i.e., exclusive of any additional shares issued to them as downside protection
in connection with the Rights Offering and the Exercise of Rights. 

 

		2.4	Notwithstanding anything to the contrary
                                         in this Addendum, any issuance of shares hereunder shall be subject to (a)
                                         proof by the Subscriber of ownership of the original Subscription Shares,
                                         through the Determining Date in a form reasonably acceptable to the Company; and (b)
                                         payment by the respective Subscriber to the Company of up to NIS 0.01 price-per-share
                                         as required in connection with such issuance under the rules of the TASE. Should TASE
                                         or any other regulatory authority condition its approval to the listing of such additional
                                         shares with a payment higher than NIS 0.01 per share or any other condition, the provisions
                                         of the third paragraph of Section 4.3 of the Agreement shall apply.

 

	3.	CONTINUING EFFECT OF AGREEMENT

 

Except as expressly set forth herein, the provisions
of the Agreement shall remain unchanged and in full force and effect as provided therein.

 

		4.	BINDING NATURE; FINAL SETTLEMENT 

 

		4.1	This Addendum reflects a negotiated compromise and settlement between the Parties, and therefore: (a)
shall not be deemed to constitute a precedent with respect to any future application of Sections 3 and 8 to the Agreement; and
(b) shall not be construed as an admission, stipulation or agreement by any
Party of any claim or argument of another Party raised in connection with the differences of opinion resolved hereby.

 

		4.2	This Addendum constitutes an amendment to the Agreement made in accordance with the provisions of Section 13.5 thereto, and
is therefore binding not only upon the Company and Gabriel Capital, but upon all Subscribers.

 

		4.3	The Parties hereby acknowledge and agree that this Addendum is made and entered into by the Company in reliance on the finality
and irrevocability of the Subscribers’ consent, given by Gabriel Capital’s execution hereof, to accept the arrangements
set forth herein as full and final satisfaction of their rights under the Agreement in connection with the Rights Offering and
the Exercise of Rights, and their irrevocable waiver hereby of any claim for rights, equity or compensation in connection with
said Rights Offering and Exercise of Rights, beyond those set forth in Section 2 above.

 

~ Remainder of page intentionally left blank;
signature page follows. ~ 

 

    	Intec
                                         Pharma » Addendum To Subscription Agmt v-7	Page
                                         2 of 3

    	 

    

  

In
Witness Whereof, the Company
and Gabriel Capital, on behalf of all Parties, have set their signatures as of the Effective Date.

 

	Intec
    Pharma Ltd.	 	Gabriel
    Capital Management (GP) Ltd.
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 /s/ Giora Carni	 	 	 
	By:	 Giora Carni 	 	By:	/s/ Gabriel Capital Management (GP) Ltd. 
	 	(Printed
    Name & Title)	 	 	(Printed
    Name & Title)

 

    	Intec Pharma » Addendum To Subscription Agmt v-7	Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]